Get the Stockscreener App
2.395
0.83%
-0.005
Macrogenics Inc stock is traded at $2.395, with a volume of 270.73K.
It is down -0.83% in the last 24 hours and down -26.32% over the past month.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
See More
Previous Close:
$2.40
Open:
$2.4
24h Volume:
270.73K
Relative Volume:
0.47
Market Cap:
$150.63M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-1.5158
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
-13.77%
1M Performance:
-26.32%
6M Performance:
-31.01%
1Y Performance:
-86.15%
1-Day Range:
$2.33
$2.445
1-Week Range:
$2.33
$2.785
52-Week Range:
$2.33
$21.88
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
2.39 | 150.63M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.81 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.42 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
618.40 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.02 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
269.10 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
MacroGenics, Inc. (NASDAQ:MGNX) Not Doing Enough For Some Investors As Its Shares Slump 26% - Simply Wall St
Levi & Korsinsky Reminds Shareholders of an Investigation into MacroGenics, Inc. (MGNX) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
MacroGenics: Stacking Up A Lot Of Headwinds... But It's Fallen Too Far - Seeking Alpha
MacroGenics to Participate in Upcoming Investor Conferences - GlobeNewswire
How Will MacroGenics Address Investors at Three Key Healthcare Conferences? - StockTitan
MacroGenics CEO departure date extended amid search for successor By Investing.com - Investing.com Australia
MacroGenics (MGNX) to Release Earnings on Thursday - Defense World
MacroGenics, Inc. to Host Earnings Call - ACCESS Newswire
Shareholders of MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights – MGNX - ACCESS Newswire
MacroGenics CEO departure date extended amid search for successor - Investing.com India
MacroGenics Extends CEO’s Separation Agreement - TipRanks
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc.(MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Shareholders that lost money on MacroGenics, Inc.(MGNX) should contact Levi & Korsinsky about pending Class ActionMGNX - ACCESS Newswire
Shareholders that Lost Money on MacroGenics, Inc. (MGNX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
MacroGenics, Inc. (MGNX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Investor Network: MacroGenics, Inc. to Host Earnings Call - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics LawsuitMGNX - ACCESS Newswire
MacroGenics, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsMGNX - ACCESS Newswire
Macrogenics VP Beth Smith sells $1,082 in common stock By Investing.com - Investing.com South Africa
Macrogenics VP Beth Smith sells $1,082 in common stock - Investing.com
Macrogenics Stock Hits 52-Week Low at $2.91 Amid Sharp Decline - MSN
Shareholders that lost money on MacroGenics, Inc.(MGNX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMGNX - ACCESS Newswire
The Curious Case of MacroGenics: A Cautionary Tale for Investors - Mi Valle
The past year for MacroGenics (NASDAQ:MGNX) investors has not been profitable - Yahoo Finance
MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug TrialHagens Berman - ACCESS Newswire
SG Americas Securities LLC Purchases 17,577 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Cancer Index takes hit in 2024 amid regulatory setbacks, failures - BioWorld Online
MGNX stock plunges to 52-week low, hitting $2.37 - Investing.com
MGNX stock plunges to 52-week low, hitting $2.37 By Investing.com - Investing.com Nigeria
Macrogenics Inc (MGNX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Further weakness as MacroGenics (NASDAQ:MGNX) drops 11% this week, taking one-year losses to 86% - Simply Wall St
Recent Insider Activity Suggests Potential Gains for Macrogenics Inc (MGNX) - Knox Daily
Ratio Revelations: Macrogenics Inc (MGNX)’s Financial Metrics in the Spotlight - The Dwinnex
Lost Money on MacroGenics, Inc. (MGNX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Can Macrogenics Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Macrogenics Inc (MGNX) Stock Observes -39.73% 200-Day Moving Average - The News Heater
Investigation Alert: MacroGenics, Apellis Pharmaceuticals, - GlobeNewswire
Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and MaplebearJohnson - The Bakersfield Californian
Holdings of Macrogenics Inc (MGNX) are aligned with the stars - SETE News
Macrogenics Inc (MGNX) deserves closer scrutiny - US Post News
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of MacroGenics, Inc.(MGNX) Shareholders - ACCESS Newswire
Ratio Review: Analyzing Macrogenics Inc (MGNX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics, Inc. LawsuitMGNX - ACCESS Newswire
MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of “Hold” from Brokerages - Defense World
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
JPMorgan Chase & Co. Reduces Stock Position in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Macrogenics Inc Stock (MGNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Karrels James | SVP, CFO and Secretary |
Feb 15 '25 |
Option Exercise |
0.00 |
14,998 |
0 |
192,591 |
| Koenig Scott | President and CEO |
Feb 15 '25 |
Option Exercise |
0.00 |
42,329 |
0 |
777,415 |
| Peters Jeffrey Stuart | Senior VP and General Counsel |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
18,858 |
| Risser Eric Blasius | Chief Operating Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
62,422 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Option Exercise |
0.00 |
1,095 |
0 |
9,955 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Sale |
2.56 |
423 |
1,083 |
9,532 |
| Spitznagel Thomas | Sr VP, Technical Ops |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
26,922 |
| Eck Stephen L. | Chief Medical Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
34,319 |
| Eck Stephen L. | Chief Medical Officer |
Feb 08 '25 |
Option Exercise |
0.00 |
11,168 |
0 |
20,966 |
| SIEGEL JAY PHILIP | Director |
May 20 '24 |
Option Exercise |
0.00 |
4,500 |
0 |
4,500 |
1.35%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):